Cardiff Oncology (CRDF) Amortizatization of Intangibles (2014 - 2025)
Cardiff Oncology (CRDF) posted Amortizatization of Intangibles of $158000.0 for Q4 2025, down 37.3% sequentially from $252000.0 in Q3 2025, and little changed YoY from $158000.0 in Q4 2024.
Cardiff Oncology (CRDF) Amortizatization of Intangibles (2014 - 2025) Analysis & Trends
Cardiff Oncology has reported Amortizatization of Intangibles for 9 years, with the latest figure at $158000.0 in Q4 2025.
- Quarterly Amortizatization of Intangibles changed 0.0% year-over-year to $158000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $848000.0 (up 41.81% YoY) and the FY2025 annual result came in at $848000.0, up 41.81% from the prior year.
- Amortizatization of Intangibles eased to $158000.0 in Q4 2025 per CRDF's latest filing, from $252000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $311000.0 in Q3 2023 and troughed at -$494000.0 in Q2 2021.
- A 5-year average of $6400.0 and a median of $146500.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles plunged 69.61% in 2022, then jumped 412.5% in 2023.
- Over 5 years, Amortizatization of Intangibles stood at -$447000.0 in 2021, then surged by 108.95% to $40000.0 in 2022, then surged by 412.5% to $205000.0 in 2023, then decreased by 22.93% to $158000.0 in 2024, then changed by 0.0% to $158000.0 in 2025.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $158000.0, $252000.0, and $301000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 158,000.00 |
| Dec 31, 2025 | 158,000.00 |
| Sep 30, 2025 | 252,000.00 |
| Sep 30, 2025 | 252,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Mar 31, 2025 | 137,000.00 |
| Mar 31, 2025 | 137,000.00 |
| Dec 31, 2024 | 158,000.00 |
| Dec 31, 2024 | 158,000.00 |
| Sep 30, 2024 | 157,000.00 |
| Sep 30, 2024 | 157,000.00 |
| Jun 30, 2024 | 127,000.00 |
| Jun 30, 2024 | 127,000.00 |
| Mar 31, 2024 | 156,000.00 |
| Mar 31, 2024 | 156,000.00 |
| Dec 31, 2023 | 205,000.00 |
| Dec 31, 2023 | 205,000.00 |
| Sep 30, 2023 | 311,000.00 |
| Sep 30, 2023 | 311,000.00 |